A single immunization with a dry powder anthrax vaccine protects rabbits against lethal aerosol challenge

Vaccine

Volumn 26, Issue 43, 2008, Pages 5494-5502

  Klas, S D ^a   Petrie, C R ^a   Warwood, S J ^a   Williams, M S ^a   Olds, C L ^a   Stenz, J P ^a   Cheff, A M ^a   Hinchcliffe, M ^b   Richardson, C ^a   Wimer, S ^a  

^a LigoCyte Pharmaceuticals Inc   (United States)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Anthrax; Dry powder vaccine; Intranasal; Protective antigen; Single dose vaccine

Indexed keywords

ALUMINUM HYDROXIDE; ANTHRAX VACCINE; CHISYS; CHITOSAN; CONJUGATED BACILLUS ANTHRACIS CAPSULE PEPTIDE; NEUTRALIZING ANTIBODY; PHOSPHORYL LIPID A; RECOMBINANT ANTHRAX PROTECTIVE ANTIGEN; UNCLASSIFIED DRUG;

AEROSOL; ANIMAL EXPERIMENT; ANTHRAX; ANTIBODY BLOOD LEVEL; ARTICLE; BACILLUS ANTHRACIS; BACTERIAL MEMBRANE; BACTERIAL SPORE; CONTROLLED STUDY; DRUG FORMULATION; DRY POWDER; FEMALE; IMMUNIZATION; INFECTION PREVENTION; NONHUMAN; PRIORITY JOURNAL; RABBIT; SINGLE DRUG DOSE; VACCINE PRODUCTION;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; AEROSOLS; ALUM COMPOUNDS; ANIMALS; ANTHRAX; ANTHRAX VACCINES; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL CAPSULES; CHEMISTRY, PHARMACEUTICAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNOGLOBULIN G; INDICATORS AND REAGENTS; NEUTRALIZATION TESTS; POWDERS; RABBITS; SOLUTIONS; VACCINES, SUBUNIT; VACCINES, SYNTHETIC;

EID: 52149108466     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.07.062     Document Type: Article

References (57)

1. Pile J.C., Malone J.D., Eitzen E.M., and Friedlander A.M. Anthrax as a potential biological warfare agent. Arch Intern Med 158 5 (1998) 429-434
2. Dixon T.C., Meselson M., Guillemin J., and Hanna P.C. Anthrax. N Engl J Med 341 11 (1999) 815-826
3. Demicheli V., Rivetti D., Deeks J.J., Jefferson T., and Pratt M. The effectiveness and safety of vaccines against human anthrax: a systematic review. Vaccine 16 9-10 (1998) 880-884
4. Friedlander A.M. Clinical aspects, diagnosis and treatment of anthrax. J Appl Microbiol 87 2 (1999) 303
5. Hambleton P., Carman J.A., and Melling J. Anthrax: the disease in relation to vaccines. Vaccine 2 2 (1984) 125-132
6. Jernigan J.A., Stephens D.S., Ashford D.A., Omenaca C., Topiel M.S., Galbraith M., et al. Bioterrorism-related inhalational anthrax: the first 10 cases reported in the United States. Emerg Infect Dis 7 6 (2001) 933-944
7. Institute of Medicine. The anthrax vaccine. Is it safe? Does it work? (2002), National Academy Press, Washington, DC
8. van der Lubben I.M., Verhoef J.C., Borchard G., and Junginger H.E. Chitosan for mucosal vaccination. Adv Drug Deliv Rev 52 2 (2001) 139-144
9. Huang J., Mikszta J.A., Ferriter M.S., Jiang G., Harvey N.G., Dyas B., et al. Intranasal administration of dry powder anthrax vaccine provides protection against lethal aerosol spore challenge. Hum Vaccin 3 3 (2007) 64-67
10. Jiang G., Joshi S.B., Peek L.J., Brandau D.T., Huang J., Ferriter M.S., et al. Anthrax vaccine powder formulations for nasal mucosal delivery. J Pharma Sci 95 1 (2006) 80-96
11. Little S.F., Ivins B.E., Fellows P.F., Pitt M.L., Norris S.L., and Andrews G.P. Defining a serological correlate of protection in rabbits for a recombinant anthrax vaccine. Vaccine 22 3-4 (2004) 422-430
12. Wimer-Mackin S., Hinchcliffe M., Petrie C.R., Warwood S.J., Tino W.T., Williams M.S., et al. An intranasal vaccine targeting both the Bacillus anthracis toxin and bacterium provides protection against aerosol spore challenge in rabbits. Vaccine 24 18 (2006) 3953-3963
13. Little S.F., Ivins B.E., Webster W.M., Fellows P.F., Pitt M.L., Norris S.L., et al. Duration of protection of rabbits after vaccination with Bacillus anthracis recombinant protective antigen vaccine. Vaccine 24 14 (2006) 2530-2536
14. Schneerson R., Kubler-Kielb J., Liu T.Y., Dai Z.D., Leppla S.H., Yergey A., et al. Poly(gamma-d-glutamic acid) protein conjugates induce IgG antibodies in mice to the capsule of Bacillus anthracis: a potential addition to the anthrax vaccine. Proc Natl Acad Sci USA 100 15 (2003) 8945-8950
15. Zaucha G.M., Pitt L.M., Estep J., Ivins B.E., and Friedlander A.M. The pathology of experimental anthrax in rabbits exposed by inhalation and subcutaneous inoculation. Arch Pathol Lab Med 122 11 (1998) 982-992
16. Little S.F., Ivins B.E., Webster W.M., Norris S.L., and Andrews G.P. Effect of aluminum hydroxide adjuvant and formaldehyde in the formulation of rPA anthrax vaccine. Vaccine 25 15 (2007) 2771-2777
17. Price B.M., Liner A.L., Park S., Leppla S.H., Mateczun A., and Galloway D.R. Protection against anthrax lethal toxin challenge by genetic immunization with a plasmid encoding the lethal factor protein. Infect Immun 69 7 (2001) 4509-4515
18. Boyaka P.N., Tafaro A., Fischer R., Leppla S.H., Fujihashi K., and McGhee J.R. Effective mucosal immunity to anthrax: neutralizing antibodies and Th cell responses following nasal immunization with protective antigen. J Immunol 170 11 (2003) 5636-5643
19. Rhie G.E., Roehrl M.H., Mourez M., Collier R.J., Mekalanos J.J., and Wang J.Y. A dually active anthrax vaccine that confers protection against both bacilli and toxins. Proc Natl Acad Sci USA 100 19 (2003) 10925-10930
20. Sloat B.R., and Cui Z. Evaluation of the immune response induced by a nasal anthrax vaccine based on the protective antigen protein in anaesthetized and non-anaesthetized mice. J Pharm Pharmacol 58 4 (2006) 439-447
21. Sloat B.R., and Cui Z. Strong mucosal and systemic immunities induced by nasal immunization with anthrax protective antigen protein incorporated in liposome-protamine-DNA particles. Pharm Res 23 2 (2006) 262-269
22. Kobiler D., Gozes Y., Rosenberg H., Marcus D., Reuveny S., and Altboum Z. Efficiency of protection of guinea pigs against infection with Bacillus anthracis spores by passive immunization. Infect Immun 70 2 (2002) 544-560
23. Meselson M., Guillemin J., Hugh-Jones M., Langmuir A., Popova I., Shelokov A., et al. The Sverdlovsk anthrax outbreak of 1979. Science 266 5188 (1994) 1202-1208
24. Jefferds M.D., Laserson K., Fry A.M., Roy S., Hayslett J., Grummer-Strawn L., et al. Adherence to antimicrobial inhalation anthrax prophylaxis among postal workers, Washington D.C., 2001. Emerg Infect Dis 8 10 (2002) 1138-1144
25. Shepard C.W., Soriano-Gabarro M., Zell E.R., Hayslett J., Lukacs S., Goldstein S., et al. Antimicrobial postexposure prophylaxis for anthrax: adverse events and adherence. Emerg Infect Dis 8 10 (2002) 1124-1132
26. Dastur F.D., Awatramani V.P., Chitre S.K., and D'Sa J.A. A single dose vaccine to prevent neonatal tetnus. J Assoc Phys India 41 2 (1993) 97-99
27. Miecarek N., Debrie A., Raze D., Bertout J., Rouanet C., Younes A., et al. Live attenuated B. pertussis as a single-dose nasal vaccine against Whooping cough. PLos Pathogens 2 7 (2006) e65
28. Schlereth B., Rose J.K., Buonocore L., ter Meulen V., and Niewiesk S. Successful vaccine-induced seroconversion by single-dose immunization in the presence of measles virus-specific maternal antibodies. J Virol 74 10 (2000) 4652-4657
29. Huang J., Garmise R.J., Crowder T.M., Mar K., Hwang C.R., Hickey A.J., et al. A novel dry powder influenza vaccine and intranasal delivery technology: induction of systemic and mucosal immune responses in rats. Vaccine 23 6 (2004) 794-801
30. LiCalsi C., Christensen T., Bennett J.V., Phillips E., and Witham C. Dry powder inhalation as a potential delivery method for vaccines. Vaccine 17 13-14 (1999) 1796-1803
31. Mestecky J., Michalek S.M., Moldoveanu Z., and Russell M.W. Routes of immunization and antigen delivery systems for optimal mucosal immune responses in humans. Behring Inst Mitt 98 (1997) 33-43
32. Sullivan V.J., Mikszta J.A., Laurent P., Huang J., and Ford B. Noninvasive delivery technologies: respiratory delivery of vaccines. Expert Opin Drug Deliv 3 1 (2006) 87-95
33. Vajdy M., and Singh M. Intranasal delivery of vaccines against HIV. Expert Opin Drug Deliv 3 2 (2006) 247-259
34. Wu H.Y., Nahm M.H., Guo Y., Russell M.W., and Briles D.E. Intranasal immunization of mice with PspA (pneumococcal surface protein A) can prevent intranasal carriage, pulmonary infection, and sepsis with Streptococcus pneumoniae. J Infect Dis 175 4 (1997) 839-846
35. Li F., Michalek S.M., Dasanayake A.P., Li Y., Kirk K., and Childers N.K. Intranasal immunization of humans with Streptococcus mutans antigens. Oral Microbiol Immunol 18 5 (2003) 271-277
36. McNeela E.A., Jabbal-Gill I., Illum L., Pizza M., Rappuoli R., Podda A., et al. Intranasal immunization with genetically detoxified diphtheria toxin induces T cell responses in humans: enhancement of Th2 responses and toxin-neutralizing antibodies by formulation with chitosan. Vaccine 22 8 (2004) 909-914
37. Muszkat M., Greenbaum E., Ben-Yehuda A., Oster M., Yeu'l E., Heimann S., et al. Local and systemic immune response in nursing-home elderly following intranasal or intramuscular immunization with inactivated influenza vaccine. Vaccine 21 11-12 (2003) 1180-1186
38. Bielinska A.U., Janczak K.W., Landers J.J., Makidon P., Sower L.E., Peterson J.W., et al. Mucosal immunization with a novel nanoemulsion-based recombinant anthrax protective antigen vaccine protects against Bacillus anthracis spore challenge. Infect Immun 75 8 (2007) 4020-4029
39. Liu W.T., Hsu H.L., Liang C.C., Chuang C.C., Lin H.C., and Liu Y.T. A comparison of immunogenicity and protective immunity against experimental plague by intranasal and/or combined with oral immunization of mice with attenuated Salmonella serovar Typhimurium expressing secreted Yersinia pestis F1 and V antigen. FEMS Immunol Med Microbiol 51 1 (2007) 58-69
40. Youn H.J., Ko S.Y., Lee K.A., Ko H.J., Lee Y.S., Fujihashi K., et al. A single intranasal immunization with inactivated influenza virus and alpha-galactosylceramide induces long-term protective immunity without redirecting antigen to the central nervous system. Vaccine 25 28 (2007) 5189-5198
41. Flick-Smith H.C., Eyles J.E., Hebdon R., Waters E.L., Beedham R.J., Stagg T.J., et al. Mucosal or parenteral administration of microsphere-associated Bacillus anthracis protective antigen protects against anthrax infection in mice. Infect Immun 70 4 (2002) 2022-2028
42. Flick-Smith H.C., Walker N.J., Gibson P., Bullifent H., Hayward S., Miller J., et al. A recombinant carboxy-terminal domain of the protective antigen of Bacillus anthracis protects mice against anthrax infection. Infect Immun 70 3 (2002) 1653-1656
43. Mikszta J.A., Sullivan V.J., Dean C., Waterston A.M., Alarcon J.B., Dekker III J.P., et al. Protective immunization against inhalational anthrax: a comparison of minimally invasive delivery platforms. J Infect Dis 191 2 (2005) 278-288
44. Baldridge J.R., Yorgensen Y., Ward J.R., and Ulrich J.T. Monophosphoryl lipid A enhances mucosal and systemic immunity to vaccine antigens following intranasal administration. Vaccine 18 22 (2000) 2416-2425
45. Huo Z., Sinha R., McNeela E.A., Borrow R., Giemza R., Cosgrove C., et al. Induction of protective serum meningococcal bactericidal and diptheria-neutralizing antibodies and mucosal immunoglobulin A in volunteers by nasal insufflations of the Neisseria meningitidis serogroup C polysaccharide-CRM197 conjugate vaccine mixed with chitosan. Infection and Immun 73 12 (2005) 8256-8265
46. Illum L., Jabbal-Gill I., Hinchcliffe M., Fisher A.N., and Davis S.S. Chitosan as a novel nasal delivery system for vaccines. Adv Drug Deliv Rev 51 1-3 (2001) 81-96
47. Chabot D.J., Scorpio A., Tobery S.A., Little S.F., Norris S.L., and Friedlander A.M. Anthrax capsule vaccine protects against experimental infection. Vaccine 23 1 (2004) 43-47
48. Wang J.Y., and Roehrl M.H. Anthrax vaccine design: strategies to achieve comprehensive protection against spore, bacillus, and toxin. Med Immunol 4 1 (2005) 4
49. Sloat B.R., and Cui Z. Nasal immunization with anthrax protective antigen protein adjuvanted with polyriboinosinic-polyribocytidylic acid induced strong mucosal and systemic immunities. Pharm Res 23 6 (2006) 1217-1226
50. Wang T.T., Fellows P.F., Leighton T.J., and Lucas A.H. Induction of opsonic antibodies to the gamma-d-glutamic acid capsule of Bacillus anthracis by immunization with a synthetic peptide-carrier protein conjugate. FEMS Immunol Med Microbiol 40 3 (2004) 231-237
51. Kubler-Kielb J., Liu T.Y., Mocca C., Majadly F., Robbins J.B., and Schneerson R. Additional conjugation methods and immunogenicity of Bacillus anthracis poly-G-d-glutamic acid-protein conjugates. Infect Immun 74 8 (2006) 4744-4749
52. Hermanson G., Whitlow V., Parker S., Tonsky K., Rusalov D., Ferrari M., et al. A cationic lipid-formulated plasmid DNA vaccine confers sustained antibody-mediated protection against aerosolized anthrax spores. Proc Natl Acad Sci USA 101 37 (2004) 13601-13606
53. Cote C.K., Rossi C.A., Kang A.S., Morrow P.R., Lee J.S., and Welkos S.L. The detection of protective antigen (PA) associated with spores of Bacillus anthracis and the effects of anti-PA antibodies in spore germination and macrophage interactions. Microb Pathog 38 (2005) 209-225
54. Welkos S., Little S., Friedlander A., Fritz D., and Fellows P. The role of antibodies to Bacillus anthracis and anthrax toxin components in inhibiting the early stages of infection by anthrax spores. Microbiology 147 Pt 6 (2001) 1677-1685
55. Welkos S., Friedlander A., Weeks S., Little S., and Mendelson I. In-vitro characterization of the phagocytosis and fate of anthrax spores in macrophages and the effects of anti-PA antibody. J Med Microbiol 51 10 (2002) 821-831
56. Pitt M.L., Little S.F., Ivins B.E., Fellows P., Barth J., Hewetson J., et al. In vitro correlate of immunity in a rabbit model of inhalational anthrax. Vaccine 19 32 (2001) 4768-4773
57. Reuveny S., White M.D., Adar Y.Y., Kafri Y., Altboum Z., Gozes Y., et al. Search for correlates of protective immunity conferred by anthrax vaccine. Infect Immun 69 5 (2001) 2888-2893